Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the huma… Read more
Microba Life Sciences Ltd (MAP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.287x
Based on the latest financial reports, Microba Life Sciences Ltd (MAP) has a cash flow conversion efficiency ratio of -0.287x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-9.34 Million) by net assets (AU$32.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Microba Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Microba Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Microba Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Microba Life Sciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OptiCept Technologies AB
ST:OPTI
|
-0.029x |
|
Springwater Special Situations Corp
NASDAQ:SWSS
|
-0.007x |
|
TBH Global Co Ltd
KO:084870
|
0.031x |
|
Berkem Group SA
PA:ALKEM
|
-0.121x |
|
JNB Co., Ltd.
KQ:452160
|
0.039x |
|
Omni-Lite Industries Canada Inc
OTCQX:OLNCF
|
0.010x |
|
Delignit AG
XETRA:DLX
|
-0.048x |
|
Umpas Holding AS
IS:UMPAS
|
-0.256x |
Annual Cash Flow Conversion Efficiency for Microba Life Sciences Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of Microba Life Sciences Ltd from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$32.49 Million | AU$-12.01 Million | -0.370x | +2.12% |
| 2023-12-31 | AU$41.22 Million | AU$-15.57 Million | -0.378x | -18.01% |
| 2022-12-31 | AU$38.72 Million | AU$-12.39 Million | -0.320x | -2.72% |
| 2021-12-31 | AU$33.54 Million | AU$-10.45 Million | -0.312x | +35.20% |
| 2020-12-31 | AU$14.94 Million | AU$-7.18 Million | -0.481x | +14.32% |
| 2019-12-31 | AU$7.70 Million | AU$-4.32 Million | -0.561x | -94.62% |
| 2018-12-31 | AU$12.56 Million | AU$-3.62 Million | -0.288x | -- |